A carregar...
Phase II Study of Intermediate-Dose Cytarabine in Patients with Relapsed or Refractory Ewing Sarcoma: A Report from the Children's Oncology Group
BACKGROUND: Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies. Cytarabine decreases EWS/FLI1 protein levels in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma in vitro and in vivo. The purpose of this phase II clini...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2791370/ https://ncbi.nlm.nih.gov/pubmed/18989890 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.21822 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|